RespireRx Pharmaceuticals Inc (RSPI)

[davidal66]

The intriguing issues in this small trial are the efficacy with once-a-day dosing 500mg/day considering the half life of about 6-7 hours, the greater efficacy in the smaller plasma levels and those without the side effects--suggesting 500mg a day might be a little too high in this population. My inference here is that a slightly lower dose--say 400 or even 300mg might have a synergistic activity with Aricept in Alzheimer's. Recall the synergism of CX717, a sister compound of ORG 24448/CX691, and Aricept. Should we assume this is compound specific? I think not considering the patent descrption implying synergism b/w ampakines and Aricept.

I would be very interested in seeing a small trial with two dosing arms: 200mg of ORG24448 and 400mgORG24448 with 5mg of Aricept in Alzheimer's. One can postulate a phase IIb trial looking at ORG24448 in alzheimer's vis-a-vis licensing worldwide rights for cognition to Organon in exchange for upfronts and milestones with some performance milestones built int(aka the use-it-or-lose-it clause). Why Organon? Haven't they moved at a snails pace? Yes. Not my first pick, but there the only company that has a clinic ready ampakine in phase IIb without safety issues. In one permutation of such an alliance, Cortex would still keep ADHD in-house for the time being and develop this indication with a backup ampakine, allowing another deal later after phase II results. I did not expect to see any ampakine news today. Happy turkey with all the trimmings to all on this thread!